Search

Objective: to evaluate the clinical efficacy and safety of Femibion Natalcare vitamin complex containing metafolin in women of late reproductive age with MTHFR C677T genetic polymorphism who had anamnestic embryonic losses. Materials and methods. Study included 100 women of late reproductive age with MTHFR C677T genetic polymorphism and anamnestic embryonic losses. Patients of main group were divided in subgroups: first – 45 women who received folic acid (400 mcg per day) and second – 55 patients who received vitamin complex Femibion Natalcare 1 tablet daily. Prescription of medications began before preconception (6–8 weeks), intake ended at 28 weeks of gestation. Control group included 40 healthy women with physiological pregnancy. The studied parameters reflected information about the features of the pregnancy and birth. Results. After a course of prophylactic supplementation with Femibion Natalcare compared with monotherapy of folic acid, it was possible to reliably reduce cases of early pregnancy loss (p =0.03), anemia in I trimester (p =0.009), preeclampsia (p =0.014), anemia in II and III trimesters (p =0.001), placental dysfunction (p =0.0005), decrease in the level of placental hormones (p =0.014), pathology of placental development and localization (p =0.0499), fetal growth retardation (p =0, 0499), premature maturation of placenta (p =0.02), induction of labor (p =0.015), disorders of neonatal adaptation (p =0.03), neonatal jaundice (p =0.018), postpartum anemia (p =0.015). There were no cases of side effects of drugs on the mother and child. Conclusions. The use of a vitamin complex containing active folate metapholine for women of late reproductive age with MTHFR C677T genetic polymorphism and anamnestic embryonic losses had a positive effect on clinical symptoms, helps to reduce cases of perinatal pathology and impaired early neonatal adaptation.